Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer
References
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-63. doi: 10.3322/caac.21834
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48. doi: 10.3322/caac.21763
- Goodarzi E, Sohrabivafa M, Adineh HA, Moayed L, Khazaei Z. Geographical distribution global incidence and mortality of lung cancer and its relationship with the Human Development Index (HDI); an ecology study in 2018. WCRJ 2019; 6: e1354. doi: 10.32113/wcrj_20197_1354
- Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci 2021; 22: 8661. doi: 10.3390/ijms2216866
- Xia L, Liu Y, Wang Y. PD-1/PD-L1 Blockade Therapy in advanced non-smallcell lung cancer: current status and future directions. Oncologist 2019; 24(Suppl 1): S31-41. doi: 10.1634/theoncologist.2019-IO-S1-s05
- Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-29. doi: 10.1084/jem.20090847
- Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015; 125: 3384-91. doi: 10.1172/JCI80011
- Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol 2016; 7: 550. doi: 10.3389/fimmu.2016.00550
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. doi: 10.1056/NEJMoa1501824
- Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-50. doi: 10.1016/S0140-6736(15)01281-7
- Reck M, Brahmer JR. Pembrolizumab in non-small-cell lung cancer. N Engl J Med 2017; 376: 997. doi: 10.1056/NEJMc1615559
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92. doi: 10.1056/NEJMoa1801005
- Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040-51. doi: 10.1056/NEJMoa1810865
- Mathew M, Safyan RA, Shu CA. PD-L1 as a biomarker in NSCLC: challenges and future directions. Ann Transl Med 2017; 5: 375. doi: 10.21037/atm.2017.08.04
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37: 537-46. doi: 10.1200/JCO.18.00149
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülop A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 Tumor Proportion Score ≥ 50%. J Clin Oncol 2021; 39: 2339-49. doi: 10.1200/JCO.21.00174
- Amrane K, Geier M, Corre R, Léveiller G, Florence G, Lamy R, et al. First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort. Ann Oncol 2019; 30: v617. doi: 10.1093/annonc/mdz260
- Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs 2019; 37: 1266-73. doi: 10.1007/s10637-019-00843-y
- Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, et al. Clinicopathologic Correlates of First-Line Pembrolizumab Effectiveness in Patients With Advanced NSCLC and a PD-L1 Expression of ≥ 50. Cancer Immunol Immunother 2020; 69: 2209-21. doi: 10.1007/s00262-020-02613-9
- Velcheti V, Chandwani S, Chen X, Pietanza MC, Piperdi B, Burke T. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS≥50%) metastatic NSCLC at US oncology practices. Immunotherapy 2019; 11: 1541-54. doi: 10.2217/imt-2019-0177
- Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol 2019; 30: 1653-59. doi: 10.1093/annonc/mdz288
- Shah M, Marmarelis ME, Mamtani M, Hennessy S. Association between survival and very high versus high PD-L1 expression in patients receiving pembrolizumab as first-line treatment for advanced non-small cell lung cancer. Clin Lung Cancer 2022; 23: 731-6. doi: 10.1016/j.cllc.2022.07.003
- Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, et al. Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%–89%) versus very high (≥ 90 %) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab. JTO Clin Res Rep 2024; 5: 100675. doi: 10.1016/j.jtocrr.2024.100675
Language: English
Page range: 450 - 458
Submitted on: Mar 23, 2026
Accepted on: May 22, 2026
Published on: Sep 7, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Vladimir Stojsic, Bojan Zaric, Petar Simurdic, Tomi Kovacevic, Darijo Bokan, Jelena Djekic Malbasa, Tatjana Sarcev, Goran Stojanovic, Daliborka Bursac, Borislava Nikolin, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.